In a financing undertaking, Fluidigm Corporation announced the pricing of an underwritten public offering of 3,660,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of $52.2 million.
The net proceeds from this stock financing, after deducting the underwriters’ discounts and other estimated offering expenses payable by Fluidigm, will be approximately $48.7 million.
Fluidigm has also granted the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover overallotments.
Fluidigm currently plans to use the net proceeds from this financing offering, for research and development, commercialization of its products, working capital and other general corporate purposes.
The financing offering is expected to close on or about August 21, 2012, subject to the satisfaction of customary closing conditions.
Piper Jaffray & Co. and Cowen and Company, LLC are acting as the joint book-running managers for the offering.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard– latest trends in big pharma deal making activity